219 related articles for article (PubMed ID: 18062731)
21. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Hua LH; Hersh CM; Morten P; Kusel J; Lin F; Cave J; Varga S; Herrera V; Ko JJ
J Manag Care Spec Pharm; 2019 Apr; 25(4):490-498. PubMed ID: 30917079
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
23. Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis.
Hartung DM; Johnston KA; Geddes J; Bourdette DN
Neurology; 2020 Mar; 94(13):e1407-e1414. PubMed ID: 31941796
[TBL] [Abstract][Full Text] [Related]
24. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan.
West DS; Johnson JT; Hong SH
J Manag Care Pharm; 2006; 12(1):25-32. PubMed ID: 16420105
[TBL] [Abstract][Full Text] [Related]
25. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
26. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
King J; McAdam-Marx C; McCaleb R; Davis D; Bemberg GB; Johnson JT
J Manag Care Spec Pharm; 2019 Jun; 25(6):646-651. PubMed ID: 31134855
[TBL] [Abstract][Full Text] [Related]
27. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
[TBL] [Abstract][Full Text] [Related]
28. Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007-11.
Trish E; Joyce G; Goldman DP
Health Aff (Millwood); 2014 Nov; 33(11):2018-24. PubMed ID: 25367998
[TBL] [Abstract][Full Text] [Related]
29. Estimated cost savings associated with the transfer of office-administered specialty pharmaceuticals to a specialty pharmacy provider in a Medical Injectable Drug program.
Baldini CG; Culley EJ
J Manag Care Pharm; 2011; 17(1):51-9. PubMed ID: 21204590
[TBL] [Abstract][Full Text] [Related]
30. Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends.
Atzinger CB; Guo JJ
Am Health Drug Benefits; 2017 Feb; 10(1):27-36. PubMed ID: 28465766
[TBL] [Abstract][Full Text] [Related]
31. Effects of an increase in prescription copayment on utilization of low-sedating antihistamines and nasal steroids.
Meissner BL; Moore WM; Shinogle JA; Reeder CE; Little JM
J Manag Care Pharm; 2004; 10(3):226-33. PubMed ID: 15228372
[TBL] [Abstract][Full Text] [Related]
32. Health plan budget impact analysis for pimecrolimus.
Chang J; Sung J
J Manag Care Pharm; 2005; 11(1):66-73. PubMed ID: 15667234
[TBL] [Abstract][Full Text] [Related]
33. US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate.
Rome BN; Tessema FA; Kesselheim AS
JAMA Intern Med; 2020 Sep; 180(9):1165-1172. PubMed ID: 32897384
[TBL] [Abstract][Full Text] [Related]
34. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies.
Alvarez E; Nair KV; Tan H; Rathi K; Gabler NB; Maiese EM; Deshpande C; Shao Q
J Med Econ; 2023; 26(1):494-502. PubMed ID: 36970763
[TBL] [Abstract][Full Text] [Related]
35. Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil.
Cooke CE; Wong W; Lee H
J Manag Care Pharm; 2005 Oct; 11(8):674-80. PubMed ID: 16194131
[TBL] [Abstract][Full Text] [Related]
36. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system.
Dunn JD; Cannon E; Mitchell MP; Curtiss FR
J Manag Care Pharm; 2006 May; 12(4):294-302. PubMed ID: 16792435
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of health plan member use of an online prescription drug price comparison tool.
Carroll NV; Mitchell MP; Cannon HE; York BW; Oscar RS
J Manag Care Pharm; 2010; 16(9):680-92. PubMed ID: 21067254
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
[TBL] [Abstract][Full Text] [Related]
39. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
[TBL] [Abstract][Full Text] [Related]
40. Pharmacy benefit forecast for a new interferon Beta-1a for the treatment of multiple sclerosis: development of a first-line decision tool for pharmacy-budget planning using administrative claims data.
Meyer CM; Phipps R; Cooper D; Wright A
J Manag Care Pharm; 2003; 9(2):168-74. PubMed ID: 14613346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
